Helix BioPharma Corp. saw a notable decline in its stock price today, closing down 1.41%.
In today's trading session, Helix BioPharma Corp. (HBP.TO) closed at CA$1.40, reflecting a 1.41% drop. This decline raises concerns among investors about the company's financial health and future prospects.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$109.60M
52W high
$5.40
52W low
$0.95
1W change
+0.70%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 73.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+73.6% Upside
Current Price
C$1.44
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
53.8%
Annualized
90-Day Vol
73.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.20
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.36 | C$1.13 โ C$1.63 |
| 60 trading days | C$1.28 | C$0.98 โ C$1.66 |
| 90 trading days | C$1.20 | C$0.87 โ C$1.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Helix BioPharma continues to face challenges in securing capital and advancing its development objectives, which may impact stock performance in the near term.
Stock Down 1.41% Today
Helix BioPharma's market cap now stands at CA$108.46 million, reflecting investor concerns over its financial stability.
Bull case
If Helix BioPharma can secure the necessary funding and make progress on its clinical programs, there could be significant growth potential in the long run.
Bear case
Ongoing difficulties in attracting investment and a lack of positive news could lead to further declines in stock price, as seen in today's performance.
Market Performance Overview
Helix BioPharma Corp. closed at CA$1.40 today, down 1.41% from the previous trading session. This drop reflects ongoing investor skepticism about the company's financial results and capital acquisition efforts.
Investor Concerns
The absence of recent positive news and the company's struggle to secure funding have raised red flags for investors. Helix's market cap of CA$108.46 million suggests that many are wary of its future growth potential, especially in a challenging capital markets environment.
Looking Ahead
As Helix BioPharma navigates its operational and development challenges, investors should keep an eye on updates regarding funding and clinical advancements. The outcome of these efforts will be crucial in determining the stock's trajectory in the coming months. For more insights, visit our Helix BioPharma stock page.
Advertisement
